XIA-2021
Regimen
- Experimental
- Cisplatin 100 mg/m² once every 3 weeks ×2 cycles concurrent with IMRT
- Control
- Cisplatin 40 mg/m² weekly ×6 concurrent with IMRT
Population
Locoregionally advanced NPC (LANPC), three mainland China hospitals, 2011-2016, IMRT era
Key finding
The largest head-to-head RCT of cisplatin scheduling in NPC CCRT. Demonstrated that q3w high-dose cisplatin is non-inferior to weekly cisplatin for tumour control while causing significantly less acute haematological toxicity (leukopenia 16% vs 27%) and substantially less late-onset grade 3-4 hearing loss (6% vs 13%). This solidified q3w cisplatin as the dominant concurrent regimen in IMRT-era CCRT, enabling simpler outpatient delivery.
Source: PMID 34083231